Submit Manuscript  

Article Details

Contribution of Efflux Pump Activity to the Delivery of Pulmonary Therapeutics

[ Vol. 3 , Issue. 1 ]


K. O. Hamilton, M. A. Yazdanian and K. L. Audus   Pages 1 - 12 ( 12 )


To date, there are few in vitro models of the human lung that have been used to characterize multidrug resistant (MDR) efflux pump activity. It is expected that the presence of these protein transporter molecules, such as P-glycoprotein (Pgp) and the multidrug resistance protein associated protein- 1 (MRP1), might play a role in limiting drug absorption through the pulmonary epithelium, as has been reported for other epithelial drug delivery barriers such as the intestine and brain. To date, the exact role of the lung resistance related protein (LRP) in MDR is unclear. In this article, we have summarized the biochemistry, function and in vitro / in vivo modulation of Pgp and MRP1. These topics are discussed in light of pulmonary delivery of therapeutic agents, with particular emphasis being placed on the bronchial region of human airways.


Efflux Pump, Pulmonary Therapeutics, P-glycoprotein (Pgp), lung resistance related protein (LRP), Rhodamine, Transmembrane domain, Hexakis


Department of Pharmaceutical Chemistry, The University of Kansas, Simons Laboratories, 2095 Constant Avenue, Lawrence, KS 66047-3729, USA

Read Full-Text article